[Clinicopathological characteristics of human epidermal growth factor receptor-2 1+ cases in breast cancer].
The expression of the HER2 oncogene has a specific prognostic and therapeutic objective in breast cancer care. Low gene expression, called HER2-low implies the possibility of being a candidate for targeted therapy. However, there is significant variability in its interpretation, hence the importance of emphasizing its proper identification and reporting.
To estimate the proportion of cases confirmed as HER2 1+ among biopsies previously reported as HER2 1+, and to describe their clinicopathological characteristics, as well as the interobserver agreement in their classification.
Observational, retrospective, and analytical study of cases previously diagnosed as HER2-negative score 1+, which were reviewed by 2 independent pathologists.
351 cases were included, with a mean age of 59.56 years. The histological subtypes were invasive ductal carcinoma NOS (70.66%), histological grade 2 (56.92%), and SBR score 6 (41.82%), associated in 89.17% of cases with hormone receptor expression. There was agreement for the HER2-low diagnosis in 78.91% of cases, with a Cohen's kappa simple of 0.62, which is similar to some studies documented in the literature.
Agreement in the interpretation of HER2-low increases when it is performed by at least 2 pathologists; likewise, proper handling of surgical specimens in the pre-analytical phase is vital for optimal assessment, as this has a direct impact on current prognosis and treatment.
To estimate the proportion of cases confirmed as HER2 1+ among biopsies previously reported as HER2 1+, and to describe their clinicopathological characteristics, as well as the interobserver agreement in their classification.
Observational, retrospective, and analytical study of cases previously diagnosed as HER2-negative score 1+, which were reviewed by 2 independent pathologists.
351 cases were included, with a mean age of 59.56 years. The histological subtypes were invasive ductal carcinoma NOS (70.66%), histological grade 2 (56.92%), and SBR score 6 (41.82%), associated in 89.17% of cases with hormone receptor expression. There was agreement for the HER2-low diagnosis in 78.91% of cases, with a Cohen's kappa simple of 0.62, which is similar to some studies documented in the literature.
Agreement in the interpretation of HER2-low increases when it is performed by at least 2 pathologists; likewise, proper handling of surgical specimens in the pre-analytical phase is vital for optimal assessment, as this has a direct impact on current prognosis and treatment.